
BG Medicine Inc. entered into a development agreement with Siemens Healthcare (NYSE:SI) diagnostics division for a heart-failure test.
The Waltham, Mass.-based diagnostics firm will develop and commercialize a test for its galectin-3 biomarker for Siemens Healthcare Diagnostics Inc.’s automated immunoassay platforms, according to a press release.
Elevated galectin-3 levels are associated with an increased risk for heart failure, according to BG Medicine’s statement announcing the deal.
The BG Medicine manual galectin-3 assay recently won Food & Drug Administration clearance as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.
The agreement with Siemens is similar to an April 2010 deal involving the galectin-3 biomarker BG made with Alere Inc. (NYSE:ALR), formerly Inverness Medical Innovations Inc.
Leave a Reply
You must be logged in to post a comment.